Esperion Therapeutics Inc ESPR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ESPR is a good fit for your portfolio.
News
-
Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol
-
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
-
Esperion Says FDA Approves New Labels for Nexletol and Nexlizet
-
Esperion Therapeutics Gets CHMP Positive Opinion for Cholesterol Medications
-
Esperion Therapeutics' Nexletol, Nexlizet Updates Get FDA Approval
-
First Republic Bank's stock sinks after possible sale reports, Credit Suisse shares boosted by central bank borrowing and other stocks on the move
-
Esperion's stock tumbles after disclosing dispute about milestone payment
Trading Information
- Previous Close Price
- $1.84
- Day Range
- $1.81–2.03
- 52-Week Range
- $0.70–3.40
- Bid/Ask
- $1.78 / $1.85
- Market Cap
- $354.18 Mil
- Volume/Avg
- 25 / 6.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.66
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 240
- Website
- https://www.esperion.com
Comparables
Valuation
|
Metric
|
ESPR
|
INVA
|
ARQT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 8.95 | — |
Price/Book Value | — | 1.38 | 10.32 |
Price/Sales | 1.66 | 4.11 | 10.99 |
Price/Cash Flow | — | 7.69 | — |
Price/Earnings
ESPR
INVA
ARQT
Financial Strength
|
Metric
|
ESPR
|
INVA
|
ARQT
|
|---|---|---|---|
Quick Ratio | 0.84 | 7.28 | 6.38 |
Current Ratio | 1.29 | 9.03 | 7.08 |
Interest Coverage | −2.55 | 10.31 | −7.72 |
Quick Ratio
ESPR
INVA
ARQT
Profitability
|
Metric
|
ESPR
|
INVA
|
ARQT
|
|---|---|---|---|
Return on Assets (Normalized) | −84.93% | 14.79% | −64.70% |
Return on Equity (Normalized) | — | 29.29% | −204.18% |
Return on Invested Capital (Normalized) | — | 16.71% | −65.35% |
Return on Assets
ESPR
INVA
ARQT
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Vrzvzvhxz | Zvk | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Kndbxlcjn | Fbkdgl | $68.1 Bil | |
HLN
| Haleon PLC ADR | Mnjrzlwy | Dflk | $36.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Hyrppbxd | Xnwn | $14.3 Bil | |
VTRS
| Viatris Inc | Krpzflk | Cwms | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Hctrrvfs | Bjk | $12.0 Bil | |
CTLT
| Catalent Inc | Fnrprsdk | Hrswx | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Pbxfkxrb | Hlqq | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Xdgdccr | Vgcz | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Jgzyqkrm | Wbsvcl | $3.4 Bil |